{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:32:01Z","timestamp":1792369921576,"version":"4.4.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a heterogeneous, chronic inflammatory disease that negatively impacts patients\u2019 quality of life. Patient-reported outcome measures (PROMs) are used to capture patient perspectives in disease assessment, and physicians use the Disease Activity Index for Psoriatic Arthritis (DAPSA) to evaluate disease activity in PsA. The study aimed to assess the relationship between PROMs and the DAPSA score in consecutive outpatients affected by PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A cross-sectional study was conducted from March 2018 to October 2020 at the PsA clinic of the ARNAS Civico in Palermo (Italy), enrolling outpatients with PsA. Patients were assessed for their disease activity according to the DAPSA score, and PROMs, such as PHQ-9, HAQ, FACIT-F, and PsAID, were evaluated. Linear regression analysis evaluated the relationship between the DAPSA Score and the included PROMs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>158 PsA consecutive peripheral subset psoriatic arthritis outpatients were recruited. The median years of illness was 10.6 (9.3\u201311.9), and the median DAPSA score was 19.02 (9\u201333.1). The regression analysis highlighted a strong relationship between the DAPSA score and the PsAID (adjR<jats:sup>2<\/jats:sup> 26%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001), the FACIT-F (adjR<jats:sup>2<\/jats:sup> 25.4%, p\u2009&amp;lt;\u20090.0001), the HAQ (adjR<jats:sup>2<\/jats:sup> 23.7%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001), and PHQ-9 (adjR<jats:sup>2<\/jats:sup> 15%, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PROMs are strongly associated with the DAPSA score, but it allows in-depth evaluation of the impact of the disease on different domains of PsA patients\u2019 life.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1332432","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:03:10Z","timestamp":1705417390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Critical importance of patient-reported outcomes for a comprehensive assessment of psoriatic arthritis patients"],"prefix":"10.3389","volume":"10","author":[{"given":"Marika","family":"Lo Monaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Mallaci Bocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Cangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Scibetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiano","family":"Argano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: a literature review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.55563\/clinexprheumatol\/8qxo80","article-title":"Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients\u2019 perception?","volume":"41","author":"Gialouri","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the DAPSA, a psoriatic arthritis-specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.12968\/bjcn.2011.16.3.146","article-title":"Patient-reported outcome measures: an overview","volume":"16","author":"Meadows","year":"2011","journal-title":"Br J Community Nurs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"GRAPPA 3PPsA study group. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/1756-185X.14069","article-title":"Fatigue in psoriatic arthritis: is it related to disease activity?","volume":"24","author":"Lai","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/1756-185X.14298","article-title":"Depression in psoriatic arthritis: related to socio-demographics, comorbid loads or disease activity?","volume":"25","author":"Lai","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.rdc.2016.01.010","article-title":"Patient-reported outcomes in rheumatoid arthritis","volume":"42","author":"Van Tuyl","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.semarthrit.2017.09.002","article-title":"A systematic review of measurement properties of patient-reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative","volume":"47","author":"H\u00f8jgaard","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis [GRAPPA]. Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the psoriatic arthritis [PsA] Core domain set: a report from the PsA workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"J Rheumatol"},{"key":"ref15","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s10067-021-05774-9","article-title":"Disease activity indices in psoriatic arthritis: current and evolving concepts","volume":"40","author":"Gialouri","year":"2021","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","article-title":"Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis","volume":"66","author":"Chandran","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"ref19","first-page":"S14","article-title":"The health assessment questionnaire [HAQ]","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford health assessment questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s42358-020-00149-1","article-title":"Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease","volume":"60","author":"Da Cruz","year":"2020","journal-title":"Adv Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis [GRAPPA]: updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3899\/jrheum.190122","article-title":"The GRAPPA-OMERACT psoriatic arthritis working group at the 2018 annual meeting: report and plan for completing the Core outcome measurement set","volume":"95","author":"Leung","year":"2019","journal-title":"J Rheumatol Suppl"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index [PASI], nail psoriasis severity index [NAPSI], modified nail psoriasis severity index [mNAPSI], Mander\/Newcastle Enthesitis index [MEI], Leeds Enthesitis index [LEI], Spondyloarthritis research consortium of Canada [SPARCC], Maastricht ankylosing spondylitis Enthesis score [MASES], Leeds Dactylitis index [LDI], patient global for psoriatic arthritis, dermatology life quality index [DLQI], psoriatic arthritis quality of life [PsAQOL], functional assessment of chronic illness therapy-fatigue [FACIT-F], psoriatic arthritis response criteria [PsARC], psoriatic arthritis joint activity index [PsAJAI], disease activity in psoriatic arthritis [DAPSA], and composite psoriatic disease activity index [CPDAI]","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Care Res [Hoboken]"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","article-title":"Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group","volume":"44","author":"Ogdie","year":"2017","journal-title":"J Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis [PsA]: defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1093\/rheumatology\/keaa780","article-title":"Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study","volume":"60","author":"Ballegaard","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5114\/ada.2019.83629","article-title":"Prevalence and severity of fatigue in psoriasis and psoriatic arthritis","volume":"37","author":"Krajewska-W\u0142odarczyk","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40744-020-00207-6","article-title":"Depression in psoriatic arthritis: dimensional aspects and link with systemic inflammation","volume":"7","author":"Mathew","year":"2020","journal-title":"Rheumatol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1136\/ard.2008.098202","article-title":"Occurrence and correlates of fatigue in psoriatic arthritis","volume":"68","author":"Husted","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3899\/jrheum.160924","article-title":"The 12-item psoriatic arthritis impact of disease questionnaire: construct validity, reliability, and interpretability in a clinical setting","volume":"44","author":"Di Carlo","year":"2017","journal-title":"J Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/acr.24593","article-title":"Depression and anxiety reduce the probability of achieving a state of sustained minimal disease activity in patients with psoriatic arthritis","volume":"74","author":"Wong","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1332432\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:03:18Z","timestamp":1705417398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1332432\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":32,"alternative-id":["10.3389\/fmed.2023.1332432"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1332432","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"article-number":"1332432"}}